Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 22

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 22
---
 Cell and Gene Therapy for Diabetes and Ph.D. in Cell Therapy for Diabetes from the Tel Aviv University. Prof. Ariel Revel, MD (Director of Medical Affairs):Professor Ariel Revel has served since January of 2020 as Kadimastem’s Medical Affairs Director. From January 2024, Professor Revel served a Medical Doctor for Maccabi Health Care Service. Since April 2017, he has served as a professor of medicine at Tel Aviv University, a Visiting Professor at Oxford University in the UK from October 2008 to October 2009 and a Visiting Professor at Stanford University in California from October 2015 to October 2016. Additionally, from April of 2017 and until April of 2024 he served in Assaf Harofeh Medical Center. On April of 2017 until April of 2021, he served as a professor at Assaf Harofeh Medical Center. He began his medical career in August of 2000 as the head of Fertility Preservation Services at Hadassah Medical Center until May of 2017. Professor Revel received his PhD from Tel -AvivUniversity, and an M.D degree from the Hebrew University of Jerusalem. Dr. Eric Konofal, MD, Ph.D. (Head of DOXA program):Dr. Eric Konofal was appointed as our Interim Chief Scientific Officer in February 2021. Dr. Konofal is an IP expert and co -founderof NLS Pharmaceutics Ltd. Dr. Konofal has been active for more than 27 years in the field of sleep research, including narcolepsy and hypersomnia, as a clinician, scientific researcher, and drug hunter. From 2006 to date, Dr. Konofal serves as a senior medical consultant for the Pediatric Sleep Disorders Center and the Child and Adolescent Psychiatry Department at Robert Debré Hospital (APHP). Dr. Konofal received his medical doctorate and Ph.D. from the University Pierre -MarieCurie, Paris/France. Proposal:The Board of Directors proposes that the following persons shall be elected, on an advisory basis, as members of the senior management on an advisory basis: Mr.Ronen Twito (Executive Chairman and Chief Executive Officer) Prof. Michel Revel, MD, PhD (Chief Scientific Officer) Mr.Kfir Molakandov, PhD (Vice President Research and Development) Mr.Ariel Revel, MD (Director of Medical Affairs) 12. Compensation for the Members of the Board of Directors